About: Cellular Therapy Models: Ex Vivo Chimera Model by Cell Fusion

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cellular Therapy Models: Ex Vivo Chimera Model by Cell Fusion Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cellular Therapy Models: Ex Vivo Chimera Model by Cell Fusion
Creator	Siemionow, Maria Cwykiel, Joanna Cwykiel, J Siemionow, M
source	PMC
abstract	Cell fusion is a ubiquitous process fundamental to physiological and pathophysiological events common to multiple cell types and species. Performed ex vivo, cell fusion is a versatile research and therapeutic tool for gene mapping, antibody production, discovering new mechanisms in biological processes, inventing alternative therapies for cell reprogramming, restoring organ function, and creating cellular therapeutics for cancer treatment. Cell fusion can be successfully applied by creating cellular therapeutic of donor – recipient chimeric cell (DRCC) in the field of solid organ and vascularized composite allotransplantation (VCA). Immunomodulatory DRCC therapy has the potential to reduce or even eliminate the need for toxic, life-long immunosuppression and to prevent both acute and chronic rejection. This innovative VCA treatment is a combination of ex vivo created chimeric cell therapy with a short-term selective protocol of monoclonal antibody and Cyclosporine A. The utilization of short-term immunosuppressive protocol will provide the opportunity for chimeric cell engraftment, proliferation, and re-education of recipient’s immune system resulting in prolongation of allograft survival. The use of chimeric cells, as a supportive treatment for VCA, would improve the conditions of severely disfigured patients by offering safe alternative approach and providing better functional and aesthetic results compared to standard reconstructive procedures. This chapter summarizes the phenomenon, current discoveries, and advancements in the field of cell fusion, as well as introduces ex vivo creation of chimeric cells and presents potential benefits of chimeric cell-based protocols. Successful application of chimeric cell protocol in VCA experimental models will advance the field of reconstructive transplantation towards clinical trials.
has issue date	2014-10-29(xsd:dateTime)
bibo:doi	10.1007/978-1-4471-6335-0_72
bibo:pmid	24263394
has license	no-cc
sha1sum (hex)	6ff6f65742e35266d6640649dd94417b1ea93ffe
schema:url	https://doi.org/10.1007/978-1-4471-6335-0_72
resource representing a document's title	Cellular Therapy Models: Ex Vivo Chimera Model by Cell Fusion
has PubMed Central identifier	PMC7121457
has PubMed identifier	24263394
schema:publication	Plastic and Reconstructive Surgery
resource representing a document's body	covid:6ff6f65742e35266d6640649dd94417b1ea93ffe#body_text
is schema:about of	named entity 'vivo' named entity 'fundamental' named entity 'physiological' named entity 'antibody' named entity 'mechanisms' named entity 'CELLULAR THERAPY' named entity 'CANCER TREATMENT' named entity 'CELL TYPES' named entity 'ORGAN' named entity 'IS A' named entity 'SPECIES' named entity 'PERFORMED' named entity 'MODEL' named entity 'TOOL' named entity 'EX VIVO' named entity 'CELL FUSION' named entity 'MODELS' named entity 'CHIMERA' named entity 'GENE MAPPING' named entity 'THERAPEUTIC' named entity 'ALTERNATIVE THERAPIES' named entity 'CELL FUSION' named entity 'MECHANISMS' named entity 'CREATING' named entity 'UBIQUITOUS' named entity 'EVENTS' named entity 'BIOLOGICAL PROCESSES' named entity 'CELL' named entity 'MULTIPLE' named entity 'RESTORING' named entity 'PHYSIOLOGICAL' named entity 'REPROGRAMMING' named entity 'THERAPEUTICS' named entity 'CELLULAR' named entity 'ANTIBODY PRODUCTION' named entity 'PROCESS' named entity 'NEW' named entity 'RESEARCH' named entity 'EX VIVO' named entity '2C CELL' named entity 'FUNCTION' named entity 'COMMON' covid:arg/6ff6f65742e35266d6640649dd94417b1ea93ffe named entity 'cell' named entity 'species' named entity 'tool' named entity 'reprogramming' named entity 'cellular therapeutics' named entity 'Cell fusion' named entity 'Cell Fusion' named entity 'CD90' named entity 'chimeric' named entity 'drug resistance' named entity 'chimeric' named entity 'allogenic' named entity 'differentiated cells' named entity 'Schwann' named entity 'Cellular therapy' named entity 'supportive therapy' named entity 'monoclonal antibodies' named entity 'hybridomas' named entity 'chimeric' named entity 'chimeric' named entity 'murine' named entity 'cell lines' named entity 'MHC antigens' named entity 'cyclosporine' named entity 'Multinucleated cells' named entity 'tissue regeneration' named entity 'nuclear fusion' named entity 'cell type' named entity 'antigens' named entity 'chimeric' named entity 'cations' named entity 'dendritic cells' named entity 'chimeric' named entity 'femur' named entity 'lymphocyte'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software